ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB – Get Free Report)’s share price passed above its 50 day moving average during trading on Thursday . The stock has a 50 day moving average of $82.15 and traded as high as $85.68. ProShares Ultra Nasdaq Biotechnology shares last traded at $84.7260, with a volume of 2,951 shares traded.
ProShares Ultra Nasdaq Biotechnology Trading Down 1.5%
The firm has a market cap of $78.80 million, a P/E ratio of 20.68 and a beta of 1.25. The business’s fifty day simple moving average is $82.15 and its 200-day simple moving average is $81.29.
Institutional Investors Weigh In On ProShares Ultra Nasdaq Biotechnology
Large investors have recently modified their holdings of the stock. Franklin Resources Inc. bought a new stake in shares of ProShares Ultra Nasdaq Biotechnology during the 2nd quarter valued at about $32,000. Citadel Advisors LLC purchased a new position in ProShares Ultra Nasdaq Biotechnology during the 3rd quarter valued at about $307,000. Kaizen Financial Strategies purchased a new position in ProShares Ultra Nasdaq Biotechnology in the fourth quarter worth about $424,000. Finally, Palumbo Wealth Management LLC purchased a new position in ProShares Ultra Nasdaq Biotechnology in the third quarter worth about $766,000.
ProShares Ultra Nasdaq Biotechnology Company Profile
ProShares Ultra Nasdaq Biotechnology (the Fund) seeks daily investment results, before fees and expenses, that correspond to twice (200%) the daily performance of the Index. The return of the Fund for a period longer than a single trading day will be the result of each day’s returns compounded over the period, which will very likely differ from the inverse of the return of the Dow Jones United States Basic Materials Index (the Index) for that period. The Fund does not seek to achieve its stated investment objective over a period of time greater than one day.
See Also
- Five stocks we like better than ProShares Ultra Nasdaq Biotechnology
- YETI Rallies After Earnings Beat and Raised Outlook
- How the 3 Leading Quantum Firms Stack Up After Q1 Earnings
- Cisco’s Vertical Rally May Still Be in the Early Innings
- Amazon vs. Alibaba: One Is Clearly The Better Value Play right Now
Receive News & Ratings for ProShares Ultra Nasdaq Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProShares Ultra Nasdaq Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.
